Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes

Dateline City: WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Language: English Contact: Merck Media InquiriesKim Hamilton, 908-423-6831orCaroline Lappetito, 267-305-7639orMerck Investor RelationsCarol Ferguson, 908-423-4465orSamsung Media InquiriesHongSeok Ji, +82-32-455-6102orSamsung Investor RelationsSungjoon Park, +82-32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news